FDA Drug Center Head Resigns Amid Conduct Review, Faces Defamation Lawsuit

The head of the Food and Drug Administration’s drug center, Dr. George Tidmarsh, abruptly resigned today following a review of “serious concerns about his personal conduct,” according to a government spokesperson.

Dr. Tidmarsh was placed on leave Friday after officials in the Department of Health and Human Services’ Office of General Counsel were notified of the issues, and submitted his resignation this morning. HHS press secretary Emily Hilliard stated, “Secretary Kennedy expects the highest ethical standards from all individuals serving under his leadership and remains committed to full transparency.” The resignation comes as the agency faces ongoing scrutiny and staffing challenges.

Simultaneously, Aurinia Pharmaceuticals filed a lawsuit alleging Tidmarsh made “false and defamatory statements” while at the FDA, claiming he pursued a “longstanding personal vendetta” against the company’s board chair, Kevin Tang. The lawsuit details a history of conflict between Tidmarsh and Tang stemming from their time together at several pharmaceutical companies, including La Jolla Pharmaceutical. According to the complaint, a LinkedIn post by Tidmarsh questioning the clinical benefit of Aurinia’s kidney drug led to a 20% drop in the company’s stock value, wiping out over $350 million in shareholder value. This incident highlights the potential impact of public statements by FDA officials on pharmaceutical companies. More information about the FDA’s regulatory process can be found on the FDA website.

Tidmarsh’s departure is the latest in a series of leadership changes at the FDA, which has experienced over 1,000 staff departures in the past year. He had previously served as an adjunct professor at Stanford University and founded several pharmaceutical companies. The FDA’s drug center is responsible for the review and oversight of all prescription and over-the-counter medications in the United States, making its leadership crucial to public health. Recent controversies surrounding the agency, including debates over drug approvals, have increased pressure on the FDA to maintain public trust.

Officials stated they are committed to a full and transparent investigation into the allegations and will announce next steps regarding the leadership of the drug center in the coming days.